ADC Therapeutics (ADCT), a commercial-stage oncology-focused biotechnology company, will host a conference call on December 11, 2024, to review preliminary data from its LOTIS-7 Phase 1b open-label clinical trial.
This trial is evaluating the safety and efficacy of the company's lead drug, Zynlonta, in combination with an approved bispecific antibody, i.e. Roche's Glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com